PD-1/PD-L1
PD-1/Programmed death-ligand 1
Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.
PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.
All Product Categories
-
PD-1/PD-L1 Inhibitors
(349)
View all products
-
PD-1/PD-L1 Agonists
(5)
View all products
-
PD-1/PD-L1 Antagonists
(11)
View all products
-
PD-1/PD-L1 Activators
(16)
View all products
-
PD-1/PD-L1 Modulators
(7)
View all products
-
PD-1/PD-L1 Inducers
(3)
View all products
-
PD-1/PD-L1 Degraders
(13)
View all products
-
PD-1/PD-L1 Control
(1)
View all products
-
PD-1/PD-L1 Substrates
(2)
View all products
-
PD-1/PD-L1 Ligands
(7)
View all products
-
PD-1/PD-L1 Related Products (459)
Related Products (459)
-
Antibodies (8)
-
PD-L1/VISTA-IN-1
0 ImagesCat. No.: HY-170793CAS No.: 2978623-09-3PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual-target inhibitor of PD-L1 and VISTA. PD-L1/VISTA-IN-1 can block the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), thereby reactivating T cells. PD-L1/VISTA-IN-1 has anti-tumor activity.
-
HBV/HDV-IN-2
0 ImagesCat. No.: HY-161605CAS No.: 3034161-76-4HBV/HDV-IN-2 (Compd 143) is a HBV, HDV and PD-1/PD-L1 inhibitor, with an EC50 of 35 nM for T cell activation.
-
GNR-051
0 ImagesCat. No.: HY-P991349GNR-051 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. GNR-051 can be used in Solid tumours research.
-
(Rac)-BMS-1
0 ImagesCat. No.: HY-19991ACAS No.: 1675201-97-4(Rac)-BMS-1 is a racemate of BMS-1 (HY-19991A). (Rac)-BMS-1 can be used as a target protein ligand to synthesize D5B PROTAC (HY-169392).
-
PD-1/PD-L1-IN-55
0 ImagesCat. No.: HY-173464CAS No.: 3052262-83-3PD-1/PD-L1-IN-55 (compound D6) is a potent PD-1/PD-L1 inhibitor with an IC50 of 4.8 nM. PD-1/PD-L1-IN-55 promotes IFN-γ secretion and reduces the proportion of PD-L1 late apoptosis.
-
LSD1-IN-42
0 ImagesCat. No.: HY-172809LSD1-IN-42 (Compound 7ae) is an orally active LSD1 inhibitor that potently inhibits LSD1 activity (IC50 = 0.08 μM). LSD1-IN-42 downregulates PD-L1 expression and enhances T cell-mediated tumor killing effects. LSD1-IN-42 demonstrates significant anti-gastric cancer activity by inhibiting tumor cell invasion and migration.
-
PD-1/PD-L1-IN-66
0 ImagesCat. No.: HY-184295PD-1/PD-L1-IN-66 is a PD-1/PD-L1 immune checkpoint inhibitor with an IC50 of 3 nM for blocking the PD-1/PD-L1 interaction. PD-1/PD-L1-IN-66 shows good affinity for PD-L1 dimers with a Kd value of 0.75 nM. PD-1/PD-L1-IN-66 can reactivate the proliferation of cytotoxic T cells. PD-L1 ligand-2 is applicable for cancer research.
-
PD-1/PD-L1-IN-45
0 ImagesCat. No.: HY-161713PD-1/PD-L1-IN-45 (Compound 2) is an inhibitor for PD-1/PD-L1 Interaction with EC50 of 21.8 nM.
-
Castalagin
0 ImagesCat. No.: HY-N20707CAS No.: 24312-00-3Castalagin is an orally active natural product with multiple biological activities including antibacterial activity against bacteria and anti-leishmanial activity against Leishmania aethiopica. Castalagin exhibits inhibitory activity against PARP1 and DNA topoisomerase II, with an IC50 of 0.86 μM for bovine PARP1. Castalagin reduces poly (ADP-ribosyl) ation modification in cells. Castalagin binds to the cell envelope of Ruminococcus bromii, increases the ratio of CD8+/FOXP3+CD4+ T cells in the tumor microenvironment, and acts as a prebiotic to enhance the activity of anti-PD-1 therapy. Castalagin induces morphological changes in Leishmania aethiopica promastigotes and inhibits their proliferation. Castalagin inhibits PBP2a-mediated peptidoglycan layer stabilization, disrupts bacterial peptidoglycan assembly, and inhibits and disintegrates bacterial biofilms. Castalagin can be used in research related to diseases such as cancer, leishmaniasis, and bacterial infections.
-
PI3Kδ-IN-25
0 ImagesCat. No.: HY-175369PI3Kδ-IN-25 is an orally active selective PI3Kδ inhibitor (IC50 = 2.1 nM). PI3Kδ-IN-25 has IC50s of 272, 285, and 1171 nM for PI3Kα, PI3Kγ, and PI3Kβ, respectively. PI3Kδ-IN-25 inhibits AKT Ser473 phosphorylation, suppresses Treg cell proliferation, and downregulates PD-L1 expression in B16F10 cells. PI3Kδ-IN-25 exhibits anticancer effects in B16F10 melanoma and Lewis lung cancer mouse models by reducing tumor-infiltrating Treg cells and enhancing immune responses. PI3Kδ-IN-25 is potentially useful in the study of melanoma, lung cancer, and other cancers.
-
PJ27
0 ImagesCat. No.: HY-181663PJ27 is a dual PD-1/PD-L1/JAK1 inhibitor, with an IC50 of 414 nM against PD-1/PD-L1, an IC50 of 786 nM against JAK1, a Ka of 294 nM for human PD-1/PD-L1, and a Ka of 473 nM for murine PD-1/PD-L1. PJ27 promotes the infiltration of CD3+CD8+ and CD3+CD4+ cells into the tumor microenvironment and exerts a significant immune activation effect. PJ27 inhibits tumor growth in a dose-dependent manner in the LLC lung cancer mouse model. PJ27 is applicable to relevant research on lung cancer.
-
PD1-PDL1-IN 2
0 ImagesCat. No.: HY-157569CAS No.: 2566710-63-0PD1-PDL1-IN 2 (ZE132) is a potent and selective PD-1/PD-L1 inhibitor, which has robust anti-tumour activity in vivo. PD1-PDL1-IN 2 promotes cytotoxic T-cell tumour infiltration and induces IL-2 expression. In addition, PD1-PDL1-IN 2 elicits strong inhibitory effects on the mRNA expression of TGF-β.
-
STT-002
0 ImagesCat. No.: HY-P992469STT-002 is a human monoclonal antibody targeting PD-1, which can be used in cancer-related research.
-
Lon-TK
0 ImagesCat. No.: HY-169436Lon-TK is a glycolysis inhibitor + linker conjugate of LTB (HY-169434). LTB is an intelligent responsive prodrug that connects Lonidamine (Lon) (HY-B0486) and a PD-L1 inhibitor (BMS-1, HY-19991) through a thioketal linker. It significantly inhibits the glycolytic metabolism of tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK shows potential for application in photodynamic-enhanced immunotherapy research.
-
REGN-10597
0 ImagesCat. No.: HY-P992161REGN-10597, composed of an anti-huPD-1-targeting antibody and IL2Ra-IL2 moiety, is a PD-1-dependent IL-2 agonist. REGN-10597 binds PD-1 to deliver masked native IL-2 to PD-1+ T cells, engaging trimeric IL-2 receptors to activate downstream signaling. REGN-10597 can be used for the research on melanoma, prostate cancer, colorectal cancer, and ovarian cancer.
-
PD-L1-IN-7
0 ImagesCat. No.: HY-163958CAS No.: 3024733-03-4PD-L1-IN-7 (compound CB31) is an inhibitor of PD-L1, which can induce PD-L1 internalization and PD-L1 retention in cells. PD-L1-IN-7 can inhibit the interaction of PD-1/PD-L1 (IC50: 0.2 nM), change the glycosylation pattern, and promote PD-L1 degradation. PD-L1-IN-7 can also enhance T cell infiltration, amplify T cell function and the ability to kill tumor cells.
-
PD-1/PD-L1-IN-67
0 ImagesCat. No.: HY-187184PD-1/PD-L1-IN-67 is a PD-L1/PD-L1 interaction inhibitor with an IC50 of 55.11 nM. PD-1/PD-L1-IN-67 directly blocks the PD-1/PD-L1 interaction and downregulates PD-L1 expression at both mRNA and protein levels. PD-1/PD-L1-IN-67 acts synergistically with radiotherapy to inhibit cancer cell viability, clonogenic survival, migration and invasion, and induce apoptosis. PD-1/PD-L1-IN-67 can be used in the research of non-small cell lung cancer.
-
Human PD-L1 inhibitor III
0 ImagesCat. No.: HY-P2564CAS No.: 2135542-84-4
-
PD-1/PD-L1-IN-48
0 ImagesCat. No.: HY-163837PD-1/PD-L1-IN-48 (compound HD10) is a potent inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.1 nM. PD-1/PD-L1-IN-48 plays an important role in cancer research.
-
PD-1/PD-L1-IN-51
0 ImagesCat. No.: HY-168080PD-1/PD-L1-IN-51 (Compound III-4) is a PD-1/PD-L1 inhibitor (IC50: 2.9 nM for hPD-L1). PD-1/PD-L1-IN-51 directly binds to PD-L1 to block the interaction between PD-1/PD-L1 and enhances IFN-γ release. PD-1/PD-L1-IN-51 has tumor inhibitory activity.
